Arvinas Inc. (ARVN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.49 per share a year ago.
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case
I favor biotech stocks trading below cash value after setbacks; Arvinas (ARVN) fits this description, dropping 25% on Thursday after ending two Phase 3 trials. ARVN's net cash per share is over $12, presenting a 70% upside from its current $7 stock price. ARVN's remaining pipeline holds minimal value; the investment thesis hinges on its substantial cash reserves and potential for activist shareholder intervention.
Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript
Arvinas, Inc. (NASDAQ:ARVN ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - President and Chief Executive Officer Noah Berkowitz - Chief Medical Officer Andrew Saik - Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Andrew Berens - Leerink Partners Jonathan Miller - Evercore ISI Tazeen Ahmad - Bank of America Peter Lawson - Barclays Paul Choi - Goldman Sachs Srikripa Devarakonda - Truist Securities Yigal Nochomovitz - Citi Group Li Watsek - Cantor Fitzgerald Jeet Mukherjee - BTIG Sudan Loganathan - Stephens, Inc Operator Thank you for standing by. My name is Gail and I will be the operator for today's call.
Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates
Arvinas, Inc. (ARVN) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of a loss of $0.86 per share. This compares to loss of $0.97 per share a year ago.
After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)
The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
Arvinas, Inc. ARVN unveiled first-in-human data on Friday for its experimental Parkinson's disease treatment, ARV-102.
Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?
Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Arvinas, Inc. ARVN and Pfizer Inc. PFE released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or metastatic breast cancer.
Arvinas-Pfizer's breast cancer treatment meets main goal in late-stage study
Pfizer and Arvinas' experimental drug to treat a type of breast cancer met the main goal in a late-stage study, the companies said on Tuesday.
